Millennium Management LLC Has $934,000 Stake in Lexeo Therapeutics, Inc. (NASDAQ:LXEO)

Millennium Management LLC boosted its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) by 282.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 141,951 shares of the company's stock after buying an additional 104,837 shares during the period. Millennium Management LLC owned approximately 0.43% of Lexeo Therapeutics worth $934,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Janus Henderson Group PLC grew its stake in Lexeo Therapeutics by 15.3% during the 4th quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company's stock valued at $28,508,000 after acquiring an additional 576,059 shares in the last quarter. Deutsche Bank AG grew its position in Lexeo Therapeutics by 172.8% during the fourth quarter. Deutsche Bank AG now owns 13,226 shares of the company's stock valued at $87,000 after purchasing an additional 8,378 shares in the last quarter. DAFNA Capital Management LLC increased its stake in Lexeo Therapeutics by 56.9% in the 4th quarter. DAFNA Capital Management LLC now owns 393,083 shares of the company's stock valued at $2,586,000 after buying an additional 142,500 shares during the period. Corton Capital Inc. acquired a new position in Lexeo Therapeutics in the 4th quarter valued at approximately $91,000. Finally, Bridgeway Capital Management LLC purchased a new stake in Lexeo Therapeutics in the 4th quarter worth approximately $428,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

Lexeo Therapeutics Stock Up 18.7%

Shares of NASDAQ:LXEO traded up $0.61 on Friday, reaching $3.88. The company had a trading volume of 1,930,423 shares, compared to its average volume of 515,138. The stock has a market capitalization of $128.80 million, a P/E ratio of -1.23 and a beta of 1.27. The stock has a 50-day moving average price of $2.97 and a 200 day moving average price of $4.48. Lexeo Therapeutics, Inc. has a twelve month low of $1.45 and a twelve month high of $19.50. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.19). On average, equities analysts expect that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on LXEO. HC Wainwright lowered their price target on shares of Lexeo Therapeutics from $23.00 to $15.00 and set a "buy" rating on the stock in a report on Friday, May 16th. JPMorgan Chase & Co. lowered their target price on Lexeo Therapeutics from $16.00 to $10.00 and set an "overweight" rating on the stock in a research note on Friday, May 30th. Royal Bank of Canada cut their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. Chardan Capital lowered their price target on Lexeo Therapeutics from $22.00 to $20.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Finally, Leerink Partners cut their price objective on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research report on Monday, March 24th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $18.50.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.